BioMimetic Therapeutics, Inc. (BMTI)
$10.88
-0.37 (-3.29%)
| CAPS Rating |
|
|---|---|
| Open | $10.95 |
| Previous Close | $11.25 |
| Daily Range | $10.80 - $11.27 |
| 52-Week Range | $6.07 - $15.81 |
| Market Cap | $237.09M |
| P/E Ratio | 16.63 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 49,451 |
| Average Daily Volume | 389,000 |
BMTI
VS S&P 500 (SPY)
How do you think BMTI will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BMTI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BMTI News and Commentary
- UPDATE 1-BioMimetic's bone product trial disappoints, shrs tank – Reuters
- Stocks the Rich Executives Are Buying – The Motley Fool
- Treading on a Johnson & Johnson Product – The Motley Fool
Related News and Articles
- A Mostly Meaningless FDA Approval – The Motley Fool
- Biotech Bargains for Your Portfolio – The Motley Fool
- 7 of the Most Efficient Companies on the Planet – The Motley Fool
- 5-Star Stocks Poised to Pop: Diageo – The Motley Fool
- 3 China Profit Plays – The Motley Fool
- A Big Upgrade for Amylin Pharmaceuticals – The Motley Fool
- Build Your Fortune With These Winners – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- 12 Companies With Ironclad Balance Sheets – The Motley Fool
- 7 Dividend Divas – The Motley Fool
- A Schizophrenic Move by Merck? – The Motley Fool
- Do Good Without Being a Corporate Hotshot – The Motley Fool
- 52-Week Highs! What's Going On? – The Motley Fool
- 4 Platform Drugmakers to Invest In – The Motley Fool
RSS Headlines
Fool UK
